Shots:

• The P-III (AVATAR) trial evaluates the safety, tolerability, PK, and efficacy of ANAVEX 2-73 (30mg) vs PBO in 36 female patients with Rett syndrome for 7wks.
• The trial met 1EPs & 2EPs i.e., improvement of RSBQ AUC (72.2% vs 38.5%); emotional behavior symptoms (ADAMS) (52.9% vs 8.3%); c CGI-I response (72.2% vs 38.5%), reductions in Rett syndrome symptoms with changes in biomarkers (GABA & L-AAA), was well tolerated. The results were consistent with the known safety profile of ANAVEX 2-73 
• ANAVEX 2-73 has received FTD, RPDD & ODD from the US FDA for Rett syndrome. The therapy is being evaluated in the P-II/III (EXCELLENCE) study for the same indication in patients aged 5 to 17yrs.

Ref: Globe Newswire | Image: Anavex